Via M. Civitali, 1
127 articles about Recordati S.p.A
Recordati Rare Diseases Announces Multiple Scientific Abstracts to Be Highlighted at American Association of Clinical Endocrinology
Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be featured onsite at the American Association of Clinical Endocrinology (AACE) annual meeting being held in San Diego, California from May 12 – 14, 2022.
Recordati Rare Diseases Inc. Announces Availability of ISTURISA® (osilodrostat) in the United States
ISTURISA® (osilodrostat) Is Now Exclusively Available Through AnovoRx Specialty Pharmacy. In an Effort to Increase Patient Access to ISTURISA, Recordati Rare Diseases Has Established the R.A.R.E. Patient Support Program. LEBANON, N.J.--( BUSINESS WIRE )-- Recordati Rare Diseases Inc. announced today the full availability of ISTURISA® (osilodrostat) for sale and distribution in the United States. ISTURISA was approved by the US Food and Drug Administra
Recordati: Isturisa® (Osilodrostat) Approved In The U.S.
Recordati Announces US NDA Approval of Isturisa® (osilodrostat), the First and Only FDA Approved Cortisol Synthesis Inhibitor for Patients with Cushing's Disease. Company Builds Endocrinology Business Unit in the U.S.
Novartis’ Isturisa (osilodrostat) was approved for adults with Cushing’s disease who either can’t have pituitary gland surgery or who have had the surgery but still have the disease.
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma (MF-CTCL) treatment at the 49th European Society for Dermatological Research Annual Meeting 2019
Helsinn and Recordati Rare Diseases announce that a co-sponsored Symposium, organized by the two companies at the European Society for Dermatological Research Annual Meeting, , will provide a better knowledge of Chlormethine Gel’s mode of action as well as guidance on the management of the Chlormethine gel induced dermatitis.
Recordati Selects IQVIA’s OCE Technology Platform and OneKey Information Services
IQVIA and Recordati SpA announced a service alliance.
Recordati: Preliminary 2017 Results Confirm Continued Growth of Sales and Profitability. Sales +11.6%, Operating Income +24.1%, Net Income +21.6%
Consolidated revenues € 1,288.1 million, +11.6%.
Recordati: Acquires Transipeg, Transipeglib and Colopeg for the French Market
The 2016 net sales of the products in France amount to around € 10 million.
Recordati: Very Good Results In The First Nine Months 2017. Continued Growth In Sales +11.8%, Operating Income +21.8%, Net Income +20.6%. Interim Dividend € 0.42 (+20%)
These financial statements will be available today at the company's offices and on the company's website.
Recordati: Very Good Results In The First Half 2017. Continued Growth In Sales +10.7%, Operating Income +19.4%, Net Income +19.8%
Recordati: The European Commission (EC) Approves Reagila (Cariprazine) For The Treatment Of Schizophrenia
Recordati Licenses An Innovative Treatment For Neurotrophic Keratitis
AstraZeneca PLC Offloads Heart Drugs to Recordati in $300 Million Deal to Pump Up R&D
Recordati Acquires Canadian Rights To CYSTADANE (Betaine Anhydrous For Oral Solution)
Recordati Establishes Canadian Presence With Launch Of Recordati Rare Diseases Canada Inc.
Recordati: Board Approves The 2016 Accounts. Sales € 1,153.9 Million (+10.1%), Operating Income € 327.4 Million (+17.6%) And Net Income € 237.4 Million (+19.4%). 2016 Dividend € 0.70 (+16.7%)
Recordati Signs An Exclusive License Agreement With The Meyer Hospital In Florence
Recordati: Preliminary 2016 Results Confirm Continued Growth Of Revenues And Profitability. New Three Year Business Plan Presented
Recordati To Meet With The Financial Community And Specialized Press In Milan
Recordati Announces Marketing Approval For Cystadrops